What Does Wegovy® Cost? A Complete 2025 Price Guide

The Actual Wegovy® List Price in 2025

Novo Nordisk sets Wegovy's wholesale acquisition cost (WAC) at approximately $1,349 per 28-day carton for the maintenance dose (2.4 mg/dose). That figure covers four auto-injector pens. Pharmacies mark up from WAC, so the cash price a patient sees at the counter typically runs $1,349 to $1,430 depending on the dispensing pharmacy and state.

The FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity, on June 4, 2021 [1]. Adolescent approval followed on December 23, 2022 [2].

Why the Price Varies by Dose Tier

Wegovy is started at 0.25 mg weekly and escalated over 16 weeks to the 2.4 mg maintenance dose. Lower-dose starter pens cost less per carton, roughly $800 to $900 at list price, yet total first-year spending is higher than it appears because patients purchase multiple dose tiers before reaching maintenance.

How That Compares to Other GLP-1 Medications

• Ozempic® (semaglutide 0.5 to 2 mg, diabetes-labeled): WAC approximately $935/month
• Mounjaro® (tirzepatide 2.5 to 15 mg, diabetes-labeled): WAC approximately $1,069/month
• Zepbound® (tirzepatide 2.5 to 15 mg, obesity-labeled): WAC approximately $1,059/month [3]
• Saxenda® (liraglutide 3 mg, obesity-labeled): WAC approximately $1,340/month

The GLP-1 receptor agonist class as a whole carries high list prices. Semaglutide's cardiovascular benefits, demonstrated in the SELECT trial (N=17,604), where semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% vs. Placebo over a median 34.2 months [4], partly justify payer resistance to coverage: the drug's per-QALY cost is debated.

Insurance Coverage for Wegovy®

Commercial Insurance

Coverage rates have improved but remain inconsistent. A 2023 survey by FAIR Health found that fewer than half of commercially insured Americans had a plan that covered FDA-approved anti-obesity medications [5]. When coverage does apply, typical commercial cost-sharing runs $25 to $150 per month after meeting the deductible, making this the single largest factor in actual out-of-pocket cost.

Novo Nordisk's WeGoTogether® savings program offers commercially insured patients a co-pay card that can bring monthly cost to $0 for qualifying individuals, subject to a monthly cap and income thresholds [6]. Patients without insurance can access the Novo Nordisk Patient Assistance Program (PAP), which may supply Wegovy at no cost to those meeting income criteria.

Medicare and Medicaid

Medicare Part D has historically excluded drugs approved solely for weight loss under the Social Security Act. The Treat and Reduce Obesity Act (TROA) has been proposed repeatedly in Congress to reverse this exclusion. The Inflation Reduction Act of 2022 does not directly mandate anti-obesity drug coverage, though CMS has signaled potential expanded coverage beginning in 2026 [7].

Most state Medicaid programs similarly exclude Wegovy. Exceptions include a small number of states that have added coverage under special waivers.

Prior Authorization Requirements

Most plans that cover Wegovy require prior authorization. Common criteria include documented BMI meeting FDA thresholds, evidence of at least one comorbidity (hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea), failure of a structured behavioral weight-loss program for three to six months, and no contraindications such as personal or family history of medullary thyroid carcinoma or MEN2 [8].

The Novo Nordisk Savings Card and Patient Assistance Programs

WeGoTogether® Co-Pay Card

Eligible patients with commercial insurance pay as little as $0 per month, capped at a savings amount of up to $225 per 28-day supply. The card is not valid for government-funded programs including Medicare, Medicaid, TRICARE, or VA benefits. Novo Nordisk updates card terms periodically; patients should verify current limits at the official program site before relying on quoted figures.

NovoCare® Patient Assistance Program

For uninsured or underinsured patients, Novo Nordisk offers Wegovy at no cost through NovoCare when household income falls at or below 400% of the federal poverty level [6]. Applications require proof of income and a prescription from a licensed prescriber.

The $499/Month Uninsured Option

Novo Nordisk launched a direct-to-patient cash-pay option at $499/month for uninsured individuals in early 2024. This rate applies to the 2.4 mg maintenance carton and requires enrollment through an authorized program. At $499 versus the $1,349 WAC, the discount is substantial, though still a significant monthly expense for many households.

The following decision framework helps patients identify the lowest realistic cost pathway before calling a pharmacy:

Wegovy Cost Pathway Decision Framework (HealthRX 2025)

1. Do you have commercial insurance? Yes: apply the WeGoTogether co-pay card. Estimated cost: $0 to $150/month.
2. Are you uninsured with income at or below 400% FPL? Yes: apply for NovoCare PAP. Estimated cost: $0/month.
3. Are you uninsured with income above 400% FPL? Yes: enroll in the $499/month direct cash-pay option.
4. Are you on Medicare/Medicaid? Explore whether your state Medicaid covers AOMs, or wait for potential 2026 CMS expansion. Consider compounded semaglutide from an FDA-registered 503B outsourcing facility as an interim option, with your prescriber's guidance.
5. Has your insurer denied prior authorization? Request a peer-to-peer review between your prescriber and the plan's medical director. STEP-1 data (14.9% weight loss vs. 2.4% placebo, P<0.001) [9] and SELECT cardiovascular outcome data [4] support medical necessity arguments.

Compounded Semaglutide: Cost, Legality, and Safety

What Compounded Semaglutide Costs

During the 2022 to 2024 period when FDA placed semaglutide on its drug shortage list, 503A compounding pharmacies (patient-specific) and 503B outsourcing facilities (batch manufacturing) could legally compound semaglutide. Compounded versions ranged from $150 to $400 per month, making them substantially cheaper than branded Wegovy.

The FDA Shortage Resolution and Its Consequences

The FDA removed semaglutide from the shortage list in October 2024, meaning most 503A pharmacies must stop compounding it unless they meet a narrow patient-specific exemption [10]. The FDA issued warning letters to multiple compounders in late 2024 for continuing to produce compounded semaglutide after the shortage designation ended.

503B outsourcing facilities may still produce compounded semaglutide for office use under specific conditions. Patients should verify that any compounding pharmacy they use holds current 503B registration at the FDA's drug establishment search [10].

Safety Considerations for Compounded Versions

The FDA has received adverse event reports linked to compounded semaglutide, including dosing errors from products supplied as multi-dose vials requiring manual drawing. Branded Wegovy uses a fixed-dose auto-injector pen, which removes that variable. The Endocrine Society's 2023 Clinical Practice Guideline on Pharmacological Management of Obesity states that "prescribers should use FDA-approved medications when available and counsel patients on the risks of unregulated compounded products" [11].

What Is Calibrate, and How Does Its Cost Compare?

Calibrate is a metabolic health program, not a pharmacy. It pairs GLP-1 prescriptions (historically semaglutide, now tirzepatide in some markets) with coaching, food tracking, and lab work. The program fee runs approximately $199 per month or $1,600 to $1,800 per year for the coaching platform.

The GLP-1 drug cost is separate from the Calibrate program fee. Patients pay their pharmacy's usual price (or use their insurance co-pay) on top of the program subscription. Total annual cost through Calibrate can therefore reach $3,200 to $18,000 depending on drug coverage status, making it one of the more expensive telehealth weight-loss program structures.

What Calibrate Includes

• Initial metabolic lab panel and physician consultation
• Assigned health coach with weekly check-ins
• Curriculum covering food, sleep, exercise, and emotional health
• GLP-1 prescription routing to preferred pharmacies

How Calibrate Compares to Direct GLP-1 Telehealth

Services such as HealthRX, Ro Body, Hims and Hers, and Found also prescribe GLP-1 medications via telehealth. Program fees vary from $79 to $199/month, with some bundling the medication. The key question for any program is whether the drug cost is bundled or separate, and whether the prescriber performs the medical evaluation required by FDA labeling and clinical guidelines.

The American Gastroenterological Association's 2022 Clinical Practice Update on GLP-1 agonists recommends that weight-loss medication be combined with behavioral intervention, supporting the program-plus-drug model in principle [12]. The evidence that structured behavioral coaching adds incrementally to GLP-1 outcomes beyond the drug itself remains limited. STEP-5 (N=304, 104-week duration) demonstrated sustained 15.2% weight loss with semaglutide alone, with behavioral support standardized across arms [13].

Total First-Year Cost Projections by Coverage Scenario

The numbers below assume a standard 16-week titration (0.25 mg to 0.5 mg to 1 mg to 1.7 mg to 2.4 mg) plus eight months at 2.4 mg maintenance.

| Coverage Scenario | Estimated Annual Drug Cost | |---|---| | Commercial insurance with co-pay card | $0 to $1,800 | | Uninsured, NovoCare PAP (income <400% FPL) | $0 | | Uninsured, $499/month cash-pay program | ~$5,988 | | Uninsured, full WAC cash price | ~$14,500 to $16,000 | | 503B compounded semaglutide (where legal) | ~$1,800 to $4,800 |

These projections exclude program fees, lab work, provider visits, and any co-insurance for associated care.

Clinical Efficacy That Justifies the Price Discussion

Any cost analysis should be grounded in what Wegovy actually delivers. The STEP program across four phase 3 trials established the efficacy profile:

• STEP-1 (N=1,961, 68 weeks): 14.9% mean weight loss with semaglutide 2.4 mg vs. 2.4% with placebo (P<0.001) [9]
• STEP-2 (N=1,210, 68 weeks, type 2 diabetes): 9.6% mean weight loss vs. 3.4% with placebo [14]
• STEP-3 (N=611, 68 weeks, intensive behavioral therapy): 16.0% mean weight loss with semaglutide [15]
• STEP-5 (N=304, 104 weeks): 15.2% weight loss, demonstrating durability [13]
• SELECT (N=17,604, median 34.2 months): 20% reduction in MACE for patients with overweight/obesity and established cardiovascular disease, no diabetes [4]

The SELECT trial is particularly relevant to payer arguments. A cardiovascular outcome benefit of that magnitude in a population that costs Medicare and commercial payers substantially in hospitalizations and procedures shifts the cost-effectiveness calculation. The Institute for Clinical and Economic Review (ICER) estimated Wegovy's value-based price range at $7,500 to $9,800 per year based on 2023 evidence [16], well below the current list price.

Weight Regain After Stopping

STEP-4 (N=803) demonstrated that patients who discontinued semaglutide after 20 weeks of treatment regained two-thirds of their prior weight loss by week 68 [17]. This means Wegovy is effectively a long-term or indefinite therapy for most patients, multiplying total lifetime cost. That reality makes insurance coverage and sustainable co-pay programs the central financial variable, not the list price in isolation.

How to Reduce Wegovy Cost: Practical Steps

Step 1: Check Your Formulary Before Prescribing

Ask your insurer for the specific formulary tier for NDC 00169-4130-11 (Wegovy 2.4 mg) before the prescription is written. Tier placement determines co-pay, and some plans cover Ozempic (diabetes-labeled semaglutide) at a lower tier than Wegovy, which a prescriber with appropriate clinical documentation might consider for off-label obesity treatment in certain cases.

Step 2: Use GoodRx or Similar Discount Programs Strategically

GoodRx and similar discount cards may reduce the cash price at some pharmacies. However, the $499/month Novo Nordisk cash-pay program often beats GoodRx pricing on Wegovy specifically. Patients should price-check both options at their dispensing pharmacy.

Step 3: Appeal Denials With Trial Data

Insurers who deny prior authorization for Wegovy can be appealed. The STEP-1 trial's demonstration of 14.9% weight loss [9] and SELECT's 20% MACE reduction [4] are publishable-quality evidence for medical necessity. The Obesity Medicine Association's position statement supports appealing denials using peer-reviewed trial data [18].

Step 4: Explore Manufacturer-Supported Titration Packs

Novo Nordisk has periodically offered starter packs at reduced cost for dose escalation phases. These are prescription-specific and pharmacy-dependent. Ask the prescriber's office whether any active titration programs apply at the time of prescribing.

Step 5: Consider Zepbound® as an Alternative

Eli Lilly's Zepbound (tirzepatide 2.5 to 15 mg) received FDA approval for obesity in November 2023 [3] and produced 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) vs. 3.1% with placebo [19]. Eli Lilly offers a savings card reducing cost to $550/month for uninsured patients and a direct cash-pay vial option at approximately $399/month for lower doses. For patients without insurance coverage, Zepbound's lower cash-pay entry point may be a clinically and financially reasonable alternative.

Regulatory and Market Context

The FDA's removal of semaglutide from the shortage list in October 2024 and subsequent compounding restrictions have effectively funneled patients back toward branded Wegovy or Zepbound, at least until biosimilar semaglutide enters the market. Ozempic's (and Wegovy's) composition patent is expected to expire around 2026 in the U.S., though method-of-use patents may extend exclusivity further.

The Endocrine Society's 2023 guidelines recommend that "anti-obesity pharmacotherapy be considered as an adjunct to lifestyle intervention for patients with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with weight-related comorbidities" [11]. Those guidelines do not specifically address cost, but the endorsement of pharmacotherapy as a standard-of-care adjunct strengthens payer coverage arguments.

CMS issued a proposed rule in November 2024 that would require Medicare Advantage plans to cover anti-obesity medications for certain high-risk beneficiaries, with implementation potentially beginning in 2026 [7]. If finalized, this could dramatically reduce out-of-pocket costs for the 66 million Medicare beneficiaries who currently lack coverage.